Podcasts about Gastroenterology

What does preventive care really mean for people living with inflammatory bowel disease (IBD)? In this episode, we break down the latest ACG Clinical Guideline Update: Preventive Care in IBD with two of its lead authors, Dr. Francis Farraye (Mayo Clinic, Jacksonville, FL) and Dr. Freddy Caldera (University of Wisconsin School of Medicine and Public Health). Together, we explore: Why preventive care is critical in IBD management Key vaccination recommendations for IBD patients How to prioritize cancer and bone health screening The role of mental health and lifestyle in long-term outcomes Produced in collaboration with the American College of Gastroenterology's Patient Care Committee, this episode offers clear, evidence-based insights for both patients and providers.  

Send us a textImagine visiting your gastroenterologist and feeling comfortable enough to discuss every aspect of how IBD affects your life—including your sexual health and practices. For many patients, particularly those in the LGBTQI+ community, this remains an elusive dream rather than reality.Dr. Victor Chedid, gastroenterologist and director of Mayo Clinic's Pride Clinic, joins Bowel Moments to tackle this crucial gap in IBD care. With disarming honesty and clinical expertise, he reveals why addressing sexuality isn't just about inclusivity—it's about providing complete medical care. When 95% of providers believe discussing sexual health is important but only 27% actually do it, patients suffer in silence with questions that directly impact their quality of life.The conversation dives deep into practical approaches for both patients and providers. Dr. Chedid shares his framework for discussing sexual practices with patients, from the straightforward question "What do you do for sex?" to navigating complex conversations around surgical interventions like J-pouch formation. For transgender patients, he unpacks recent research on gender-affirming hormones and IBD, emphasizing that life-saving gender-affirming care should never be withheld due to IBD concerns.Perhaps most compelling is Dr. Chedid's perspective on cultural humility and intersectionality. Each patient's experience is shaped by multiple overlapping identities—their sexuality, gender, race, nationality, and more. Rather than making assumptions, he advocates for providers to "leave their biases at the door" and approach each person's unique situation with curiosity and respect."People living with IBD are the experts of their own bodies," Dr. Chedid reminds us in his powerful closing thoughts. "When they say something feels off, it's not a guess—it's lived experience." This principle forms the foundation of truly inclusive care—care that sees patients as whole people deserving of dignity, understanding, and comprehensive treatment.Ready to advocate for more inclusive IBD care? Share this episode with your healthcare team and join the conversation about creating safe spaces for everyone in our community.Links: AGA's Pride Month Provider Spotlight on Dr. ChedidDr. Chedid talking about forming the IBD Pride Clinic"Your Top 6 Questions Answered by Dr. Victor Chedid" -A Program Dedicated to IBD Patients from the LGBTQIA+ Community- Crohn's & Colitis Foundation- USALet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

In this enlightening episode of the Productivity Smarts Podcast, host Gerald J. Leonard sits down with Dr. Mohammad Farivar, a board-certified gastroenterologist and author of “Is It IBS or Your Diet?”. With more than 55 years of medical experience, Dr. Farivar brings deep insights into the connection between gut health, productivity, and overall well-being.   Many people struggle with Irritable Bowel Syndrome (IBS), a condition that can drastically impact daily life, work performance, and even mental clarity. Dr. Farivar reveals how diet, stress, and gut health play pivotal roles in both IBS symptoms and productivity and why traditional treatments often miss the mark.   Through real-life patient stories and science-backed strategies, you'll discover how small dietary shifts, the right testing, and an informed approach to gut health can make a world of difference.   Whether you or someone you know is battling digestive health issues, this conversation will equip you with practical steps to regain control and unlock your full potential.   What We Discuss [00:00] Introduction to Dr. Mohammad Farivar [05:47] Impact of IBS on patients' lives [09:12] Motivation to write the book [12:19] Proper approach to IBS diagnosis [15:12] IBS and productivity loss [17:21] Stress and its effects on IBS [22:54] Critique of probiotic industry [27:16] FODMAP diet explained [30:44] Complementary and alternative medicine for IBS [32:44] Hydrogen breath test for IBS [37:19] Where to find the book and final advice   Notable Quotes [05:03] “We are all born with a mission. Even as a child, I knew I wanted to be a doctor.” – Dr. Farivar   [06:39] “In my practice, I was able to find the cause of IBS in more than 90% of cases — most of the time, it was diet-related.” – Dr. Farivar   [15:12] “IBS is the second most common cause of lost productivity after colds and infections.” – Dr. Farivar   [22:59] “Forget probiotics. A spoonful of yogurt gives you more than any pill.” – Dr. Farivar   Resources   Dr. Mohammad Farivar Website - IsItIBSOrYourDiet.com LinkedIn: Mohammad Farivar Book: Is It IBS or Your Diet?   Productivity Smarts Podcast Website - productivitysmartspodcast.com   Gerald J. Leonard Website - geraldjleonard.com Turnberry Premiere website - turnberrypremiere.com Scheduler - vcita.com/v/geraldjleonard Kiva is a loan, not a donation, allowing you to cycle your money and create a personal impact worldwide. https://www.kiva.org/lender/topmindshelpingtopminds

Listen as pulmonologist Peter Dicpinigaitis discusses his approach to the diagnosis and management of patients with refractory chronic cough in the context of a clinically relevant case and provides insights regarding emerging therapies.PresenterPeter Dicpinigaitis, MDProfessor of MedicineAlbert Einstein College of MedicineDivision of Critical Care MedicineMontefiore Medical CenterDirector, Montefiore Cough CenterBronx, New YorkLink to full program:https://bit.ly/4kweynG

Send us a textThis discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Louise drives this conversation based on two related issues she sees emerging: (i) increasing opportunities for motivated patients to manage their own health and (ii) managing the total patient in an environment where people may be taking incretin agonists as if they are consumer drugs. With increased access to scanning, providers can monitor patients (and patients can self-monitor) more closely. However, some of the issues a provider might find are tricky: patients who undertake what Louise describes as "the sneaky areas patients think are normal, but are probably contributing to disease" due to miseducation or no education on healthy eating and lifestyle, or patients purchasing and using incretin agonists through consumer channels, but possibly at subtherapeutic doses. Vigilance and probing are key here, but health systems will need to train more people on the types of probing that uncover underlying issues and behaviors that patients mistakenly believe to be healthy. The discussion also extends to the role of NITs in diagnosis and patient management, and how providers need to shift the paradigm away from describing a patient by fibrosis stage and instead focus on the amount of fat in the liver and its overall suppleness.

In this episode, hosts Drs. Peter Lu and Jason Silverman talk to Dr. Justine Turner about a non-biopsy approach to diagnosis for celiac disease in children. Dr. Turner is a Professor of Pediatrics and Divisional Director for the Division of Gastroenterology and Nutrition at the University of Alberta and also the medical lead for the Multidisciplinary Pediatric Celiac Disease Clinic at Stollery Children's Hospital in Edmonton. Learning Objectives:Review current clinical guidelines for the diagnosis of celiac disease in childrenUnderstand the potential pros and cons of a non-biopsy approach to diagnosis for celiac diseaseRecognize the potential impacts of serologic diagnosis for celiac disease on patients, their families and healthcare systemsLinks (to be added!!):Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and NutritionNASPGHAN Clinical Report on the Diagnosis and Treatment of Gluten-related DisordersEuropean Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020Positive Predictive Value of Tissue Transglutaminase IgA for Celiac DiseaseSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Chengwei Tang and Associate Professor Zhiyin Huang from the Department of Gastroenterology, West China Hospital of Sichuan University, Chengdu, Sichuan, China on the paper "Parecoxib sequential with imrecoxib for occurrence and remission of severe acute pancreatitis: a multicentre, double-blind, randomised, placebo-controlled trial" published in paper copy in Gut in September 2025. Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://spoti.fi/3Ifxq9p).

Contributor: Alec Coston, MD Educational Pearls: Hepatic encephalopathy (HE) is defined as a disruption in brain function that results from impaired liver function or portosystemic shunting. Manifests as various neurologic and psychiatric symptoms such as confusion, inattention, and cognitive dysfunction Although ammonia levels have historically been recognized as important criteria for HE, the diagnosis is ultimately made clinically. An elevated ammonia level lacks sensitivity and specificity for HE Trends in ammonia levels do not correlate with disease improvement or resolution A 2020 study published in the American Journal of Gastroenterology evaluated 551 patients diagnosed with hepatic encephalopathy and treated with standard therapy Only 60% of patients had an elevated ammonia level, demonstrating the limitations of ammonia levels However, a normal ammonia level in a patient with concern for HE should raise suspicion for other pathology. In patients with cirrhosis presenting with neuropsychiatric symptoms, consider HE as the diagnosis after excluding other potential causes of altered mental status (i.e., Seizure, infection, intracranial hemorrhage) The primary treatment is lactulose Works by acidifying the gastrointestinal tract. Ammonia (NH₃) is converted into ammonium (NH₄⁺), which is poorly absorbed and subsequently eliminated from the body Also exerts a laxative effect, further enhancing elimination References: Haj M, Rockey DC. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis. Am J Gastroenterol. 2020 May;115(5):723-728. doi: 10.14309/ajg.0000000000000343. PMID: 31658104. Lee F, Frederick RT. Hepatic Encephalopathy-A Guide to Laboratory Testing. Clin Liver Dis. 2024 May;28(2):225-236. doi: 10.1016/j.cld.2024.01.003. Epub 2024 Jan 30. PMID: 38548435. Vilstrup, Hendrik1; Amodio, Piero2; Bajaj, Jasmohan3,4; Cordoba, Juan1,5; Ferenci, Peter6; Mullen, Kevin D.7; Weissenborn, Karin8; Wong, Philip9. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60(2):p 715-735, August 2014. | DOI: 10.1002/hep.27210 Weissenborn K. Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles. Drugs. 2019 Feb;79(Suppl 1):5-9. doi: 10.1007/s40265-018-1018-z. PMID: 30706420; PMCID: PMC6416238. Summarized by Ashley Lyons, OMS3 | Edited by Ashley Lyons & Jorge Chalit, OMS4 Get your tickets to Tox Talks Event, Sept 11, 2025: https://emergencymedicalminute.org/events-2/ Donate: https://emergencymedicalminute.org/donate/  

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation centers on the roles that new technologies and an expanded APP population will play in MASLD and MASH management in the US, and concludes by exploring how care might look different 12 months from now, and then in subsequent years. As panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients, many comments touch on themes discussed earlier in this episode. A couple are unique. Zobair and Scott discuss the increased role that artificial intelligence and big data analytics will play in identifying high-risk patients and improving clinical pathways. Additionally, Zobair notes that we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scott anticipates a "paradigm shift" in which endocrinologists view MASH similarly to how they view retinopathy, neuropathy and retinopathy. Naim suggests that one year will not look tremendously different from today, but that five years from now will be an entirely different picture, which he describes in some detail. 

La question revient souvent : manger cru est-il forcément meilleur pour la santé ? Salades colorées, fruits frais, smoothies… Le cru évoque légèreté, vitalité et naturalité. Mais attention : si ses atouts sont réels, il n'est pas adapté à tout le monde.Les bienfaits du cruLes aliments crus conservent des vitamines et enzymes fragiles à la cuisson, comme la vitamine C ou certaines polyphénol-oxydases. Ils sont riches en fibres solubles, hydratants, faibles en calories et idéals pour ceux qui veulent "manger léger". Ils apportent aussi antioxydants et densité nutritionnelle, particulièrement intéressants pour une digestion robuste et un microbiote équilibré.Quand le cru devient difficile à digérerLe revers de la médaille ? Les fibres insolubles contenues dans certains légumes crus (chou, carotte, céleri) peuvent irriter la muqueuse digestive et provoquer ballonnements, fermentation et inconfort chez les personnes sensibles. Une étude publiée dans le World Journal of Gastroenterology (2014) a d'ailleurs montré que ces fibres aggravent les symptômes du côlon irritable.En médecine traditionnelle chinoise, on considère aussi que le cru "affaiblit le yang de la rate", c'est-à-dire la capacité du corps à transformer et assimiler les aliments. Résultat : fatigue après le repas, transit accéléré ou sensation de froid interne peuvent apparaître en cas d'excès.Trouver le bon équilibreLe cru n'est donc ni un miracle, ni un ennemi. Tout dépend du profil de chacun. Pour les personnes jeunes, toniques et sans troubles digestifs, il reste un atout nutritionnel. Pour les terrains plus fragiles, mieux vaut privilégier la cuisson douce (vapeur ou étouffée) qui assouplit les fibres, améliore l'assimilation des minéraux tout en préservant une partie des vitamines.En pratique, la meilleure approche est la modération : alterner crudités et légumes cuits, surtout en été, pour profiter des bienfaits du cru sans en subir les inconvénients.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss  FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices.This conversation starts with the group describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education. Another important benefit may come in terms of coverage. Scott points out that most patients living with obesity but not diabetes are unlikely to have their semaglutide prescriptions covered by commercial insurers. Those living with non-cirrhotic MASH are likely to have semaglutide covered. A separate but related point: Naim reports that ~30% of the MASH patients he sees are taking an incretin agonist at the time of initial visit.

Send us a text00:00:00 - Surf's Up, Season 6, Episode 12This week's episode is a special three-part roundtable on the implications of the FDA's recent approval of semaglutide. Naim Alkhouri, Manal Abdelmalek, Scott Isaacs and Zobair Younossi join Roger Green in a discussion that focuses less on specifics of pharmacotherapy and more on how having two drugs available will change MASH management in the US.00:08:45 - Part I: How Will The Semaglutide Approval Affect Patient Treatment and Pharmacotherapy?The group starts by describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education.00:25:30 - Part II: How the Structure of Medical Practice Is Likely To ChangeNaim states that many hepatologists are currently uncomfortable managing patients on GLP-1 agonists. This will need to change. Manal points out that providers must check for cirrhosis when testing for MASH and understand how to respond accordingly. An increase in the number of providers having access to in-office scanning devices will facilitate this process. Zobair states that even if all related specialists integrate MASH into their practices, the actual patient care demand will require alternative pathways in which the responsibility for patient care will rest with specialist APPs. After Naim Alkhouri describes some of the differences between resmetirom and semaglutide in terms of practical treatment decisions, the discussion focuses on why MASLD and MASH will create unique challenges for hepatology practices. Manal views the issue as a matter of time; practices cannot absorb large numbers of new, non-urgent patients. Naim suggests that the real issue is the business question: specialists today do not profit simply from treating patients. Zobair agrees with Naim and notes that the challenge is not unique to hepatology. He expresses the hope that AI and efficient database management will make it easier to target patients, screen, diagnose and treat them. 00:44:17 - Part III: What Happens Next?In this final section, panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients. Many of the comments touch on themes discussed earlier in this episode, but a couple are unique. Zobair states we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scotts anticipates a "paradigm shift" in which providers come to view MASH similarly to how they view diabetic comorbidities. 

In this special crossover podcast episode, Tuesday Night IBS hosts Jeffrey Roberts, MSEd, BSc, Erica Dermer and Kate Scarlata, MPH, RDN, are joined live by William Chey, MD, and Amanda Lynett, MS, RDN, at FOOD the Main Course Conference in Ann Arbor, MI. •    Intro :02 •    About Scarlata :30 •    About Chey 1:07 •    About Lynett 1:49 •    Chey, what are your goals for this year's FOOD the Main Course Conference? 2:58 •    How do you feel that mechanisms of diet are affecting microbiomes? 5:37 •    Amanda, what have you learned over the years as you have put together this conference, and how do you think this experience has shaped a more well-rounded program for clinicians?  8:23 •    What are you personally going to take away from the conference this year? 11:17 •    A discussion on peer-to-peer interactions, the spirit of collaborative care, and what each provider is bringing to the table. 12:22 •    Kate, tell us about why you come back to this conference every year. 17:32 •    What challenges did you overcome to move the needle forward in diet and GI conditions? 19:14 •    Chey, can you talk about the correlation between stress and diet when it comes to IBS? 24:21 •    How are we dealing with the ramifications of GLP-1s? 29:33 •    As providers, what is your first instinct when patients tell you they started GLP-1s? 32:28 •    How is the community going to help listeners weed through Internet noise to find accurate information? 35:01 •    Group discussion on the rise of severe constipation. 41:31 •    Who decides to send patients for colectomy consultations? 43:33 •    Is there anything else you want to share or highlight from the conference? 47:25 •    Thank you all 48:58 •    Thanks for listening 49:42 Erica Dermer is an IBS and Celiac Disease patient who hosts the Celiac and the Beast blog and You Had Me at Eat podcast series. Amanda Lynett MS, RDN, is a registered dietitian with her masters. Amanda is with the Division of Gastroenterology at Michigan Medical in Ann Arbor. Jeffrey Roberts, MSEd, BSc, is a patient advocate and creator of the first website for IBS sufferers. He is the co-founder of Tuesday Night IBS. Kate Scarlata, MPH, RDN, is a US-based dietitian with over 30 years of experience. Kate's expertise is in gastrointestinal disorders and food intolerance.  We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more Tuesday Night IBS, be sure check out TuesdayNightIBS.com and to follow and subscribe to their podcast. Disclosures: Chey and Roberts report no relevant financial disclosures. Scarlata reports stock options with Epicured LLC and FODY Food Company, financial support from Dr. Schar, Mahana Therapeutics, Nestle Health Science, Olipop, Pendulum, QOL Medical.

Send us a textFor two decades, Rachel Gebhardt has navigated the complex terrain of Crohn's disease with a refreshing perspective shaped by her father's experience with the same condition. Where her father let illness define him, Rachel chose a different path—one filled with humor, openness, and resilience—despite her case being more medically severe.Rachel's journey encompasses four bowel surgeries and fourteen hospital admissions since 2020 alone, including a colostomy she affectionately named "Whoopie." With disarming candor, she shares the moment her surgeon showed her a photo of a woman in an American flag bikini with a matching ostomy bag cover as encouragement—a moment that eventually inspired her own celebratory beachside photo years later. Through skin infections, bowel obstructions, and dietary restrictions, Rachel maintains her commitment to living fully and modeling positive coping for her children.The military healthcare system presented unique challenges, but also connected Rachel with Dr. Anish Patel at Brook Army Medical Center, who became not just her gastroenterologist but her advocate and ally. Their relationship exemplifies the profound difference compassionate, specialized care makes for patients with complex conditions. Rachel details her experience with hyperbaric treatments, medication complications, and the surprising remission she experienced only during pregnancy and breastfeeding—highlighting the understudied connection between hormones and IBD.What resonates most deeply is Rachel's transformation from initially viewing her ostomy as "the end of the world" to embracing it as a source of freedom. Now training for a half marathon and hiking mountains previously inaccessible when bathroom urgency controlled her life, she's become an outspoken advocate for ostomy awareness. Her message is clear and powerful: life with an ostomy can be not just manageable, but genuinely good—a perspective desperately needed by those facing similar paths. For anyone navigating IBD or supporting someone who is, Rachel's story offers both practical wisdom and heartening hope.Links: United Ostomy AssociationOur episode with Dr. Anish PatelPregnancy and Crohn's - video from Brigham & Women's IBD CenterPregnancy & Breastfeeding info- Crohn's Colitis UKLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

¿Tu abdomen cambia de un día para otro y parece que has engordado en cuestión de horas?

Diverticulosis and diverticulitis sound alike but are very different conditions—and knowing the difference is key to protecting your digestive health. In this episode, host Jacqueline Gaulin welcomes Dr. Lisa Strate, Professor and Chief of Gastroenterology and Hepatology at the University of Wisconsin, and one of the nation's leading experts in diverticular disease. Together, they clear up common questions and misconceptions about diverticulosis and diverticulitis, including: What causes these conditions and who is most at risk The symptoms and warning signs patients should watch for Whether it's possible to have one without the other How diet and lifestyle affect treatment and prevention This episode is produced in collaboration with the American College of Gastroenterology's Patient Care Committee.  

What if general practice could seamlessly connect with secondary care? In this episode, Ben speaks with Dr. Charlie Andrews, a GP at Somerset's Summer Valley Medical Group and a leading voice in gastroenterology. Charlie shares his journey and the inspiration behind pioneering specialised roles for GPs. He discusses his innovative training programme, supported by NHS England and the Southwest Endoscopy Training Academy, which empowers GPs to expand into areas like inflammatory bowel disease and endoscopy while collaborating with hospital specialists. Charlie also explores the challenges of recruiting and funding GPs for extended roles and explains the practical implementation guide that ensures smooth transitions and proper supervision. Join us for an insightful conversation about how collaboration, innovation, and passion are reshaping patient care, bridging the gap between primary and secondary care, and opening exciting new pathways for GPs across the UK. Introduction (0:09) Does anyone else offer the same training programme? (03:54) Joint working between General Practice & Secondary care.. (04:21)  A two way learning.. (06:45)  Referral and utilisation rates (07:23) Making it better for patients (08:01) The 10 year plan (08:46)  The training programme (10:17)  The placements (12:44) Funding (14:14)  Learnings so far.. (15:53)  Find out more.. (17:54) What does gastroenterology look like in 10 years time (20:17)  Getting in touch (22:28) Access the GPwER framework document here.  The GPwER course brochure can be found here. The training programme evaluation can be found here. Listen to Charlies educational podcast that he runs for the PCSG for primary care clinicians here. Contact Charlie directly via email here. For all enquiries about the Ockham podcast, please contact Ben Gowland here.

In today's episode, we spoke with Masatoshi Kudo, MD, about the evolving treatment landscape in hepatocellular carcinoma (HCC) and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens. Dr Kudo is a professor and chairman in the Department of Gastroenterology and Hepatology at Kindai University Faculty of Medicine in Osaka, Japan.

Support YDS on Patreon!This week, Zoë and Kylee tackle the carnivore diet, the internet's most extreme eating trend. From raw liver smoothies at Erewhon to shirtless influencers promising that “meat heals everything,” the carnivore diet has exploded in popularity. But what really happens when you cut out all plants and live on ribeye steaks, bacon, and bone broth?We explore the strange history of meat-only diets, from 1920s Bellevue experiments to modern influencers like Shawn Baker and Paul Saladino. We unpack the claims about plant “toxins,” the allure of ketosis, and why athletes, especially women, need carbs for performance, recovery, and hormone health. And we dig into the environmental cost of ribeye-heavy eating, why beef is one of the most resource-intensive foods on the planet, and how climate denial often gets wrapped into carnivore culture.So should you go full T-Rex? Probably not. But understanding the hype—and the risks—shows why restrictive food fads keep spreading, and why carbs are still essential for endurance athletes and long-term health.Support the ShowEternal – To check out Foundations, use the promo code YDS for 10% a one year membership.Tailwind Nutrition offers science–backed endurance fuel that actually works. Try our favorite, Blueberry Lemonade Endurance Fuel - Get 20% off your first order with code YOURDIET20Janji – Adventure-ready running gear with pockets that actually work. Use code YDS for 10% off your order.Microcosm Coaching – Human-first, athlete-centered coaching for every runner, from 5K to 100 miles and beyond.REFERENCESBurke, L. M., Ross, M. L., Garvican-Lewis, L. A., Welvaert, M., Heikura, I. A., Forbes, S. G., ... & Hawley, J. A. (2017). Low carbohydrate, high fat diet impairs exercise economy and negates the performance benefit from intensified training in elite race walkers. The Journal of Physiology, 595(9), 2785–2807. https://doi.org/10.1113/JP273230Cordain, L., Eaton, S. B., Sebastian, A., Mann, N., Lindeberg, S., Watkins, B. A., ... & Brand-Miller, J. (2005). Origins and evolution of the Western diet: Health implications for the 21st century. The American Journal of Clinical Nutrition, 81(2), 341–354. https://doi.org/10.1093/ajcn.81.2.341Hall, K. D., & Guo, J. (2017). Obesity energetics: Body weight regulation and the effects of diet composition. Gastroenterology, 152(7), 1718–1727. https://doi.org/10.1053/j.gastro.2017.01.052Jönsson, T., Granfeldt, Y., Lindeberg, S., & Hallberg, A. C. (2009). Subjective satiety and other experiences of a Paleolithic diet compared to a diabetes diet in patients with type 2 diabetes. Nutrition Journal, 8(1), 35. https://doi.org/10.1186/1475-2891-8-35Lerner, R. (1930). Adventures in diet. Harper's Monthly Magazine, 161(962), 509–518.Micha, R., Michas, G., & Mozaffarian, D. (2012). Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes: An updated review of the evidence. Current Atherosclerosis Reports, 14(6), 515–524. https://doi.org/10.1007/s11883-012-0282-8O'Hearn, A., Tro, K., & Naiman, D. (2021). Clinical experience of medical doctors with a carnivore diet. Current Developments in Nutrition, 5(Supplement_2), 393. https://doi.org/10.1093/cdn/nzab044_067Stefansson, V. (1946). Not by bread alone. New York, NY: Macmillan.UN Food and Agriculture Organization. (2013). Tackling climate change through livestock: A global assessment of emissions and mitigation opportunities. Rome: FAO.Zhang, Y., Pan, X. F., Chen, J., Xia, L., Cao, A., Zhang, Y., ... & Pan, A. (2021). Associations of red meat, processed meat, and poultry consumption with risk of colorectal cancer: A prospective cohort study of 0.5 million Chinese adults. International Journal of Cancer, 149(5), 979–989. https://doi.org/10.1002/ijc.33694

Send us a textMulti-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the second of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire spectrum of multi-metabolic diseases.This conversation starts by focusing on how the two clinics train other physicians and practices on multi-metabolic issues. The EDOM clinic in Spain is certified to provide nutritional training to other practices across the country, while the newer, smaller Trajectory Health Partners practice provides support on use of FibroScan and, more recently, Velacur from Sonic Incytes. Louise notes how important training is for optimal use of scanning devices, which includes both technical proficiency and knowledge of how to educate and motivate patients using the results of the scans. From there, the conversations shifts to focus on differences between treating patients in a conventional practice vs. a multi-metabolic one. The key differences involve length of patient visit and use of allied providers to educate patients more fully. Next, Louise asks whether the clinics have data on reducing the number of patients needing to go to a hospital. EDOM has data while the younger Trajectory has a clear sense this happens but no large-scale practice data to support this sense. Louise's last question is to ask how each physician would "sell" colleagues in their specialty on why to set up a multi-metabolic practice. The answers reflect the different specialties in which the physicians were trained originally (endocrinology in Spain, gastroenterology in the U.S.) but have significant common elements. 

Send us a textMulti-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the first of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire spectrum of multi-metabolic diseases. The core of this episode starts during the weekly groundbreaker exercise, during which our guests began to describe the path that brought them from single-disease specialization to the broader multi-metabolic practice.. Immediately after the groundbreakers, participants describe their clinics today, including patient population and principles underlying their approach to treatment. For Karen, the path started in a conventional gastrointestinal practice. A decade ago, she gained certification in obesity medicine. While treating patients for obesity, she came to appreciate the interplay of obesity, diabetes and the other manifestations of multi-metabolic disease. Eventually, she divided her practice and time so that she spent half her time in the GI practice and the other half creating Trajectory Health Partners, a practice focused on overall metabolic health.For Dr. López, the initial goal was to "re-educate the hypothalamic problem," which he saw as the root cause of obesity and from which all other metabolic issues came. He describes this as "the auto-destruction button" of patients' lives, leading to two causes of death: (1) insulin resistance and related cardiovascular problems, and (2) short-telomere cancers. The rest of this conversation focuses on the tests that the two clinics use to confirm MASLD or MASH and their approaches to treating multi-metabolic patients.

Featuring: David T. Rubin, MD, University of Chicago Medicine The GI Research Foundation was able to produce this podcast with sponsorships from Metro Infusion Center. David T. Rubin, MD, Joseph B. Kirsner Professor of Medicine and Chief of Gastroenterology, Hepatology and Nutrition at the University of Chicago Medicine, explores challenges 1–5 of the top ten faced by people with Crohn's disease and ulcerative colitis. He shares how health care providers and researchers are working to overcome these obstacles and improve patients' lives. To access other episodes of Visceral: Listen to Your Gut and learn more about the GI Research Foundation's support of clinical and laboratory research to treat, prevent, and cure digestive diseases, please visit https://www.giresearchfoundation.org/. Available on Apple Podcasts, Spotify, and everywhere else you listen.

Send us a text00:00:00 - Surf's Up: Season 6, Episode 11 This week, we modify our usual episode structure to focus on multi-metabolic practices and constructs. The multi-metabolic practices covered this week are run by non-hepatologists who have chosen to focus on the liver in a broader cardiometabolic context. They include two practices discussed during a two-part roundtable, one run by US gastroenterologist Dr. Karen Jerome-Zapadka and the EDOM practice in Spain, run by endocrinologists. The expert interview is with Dr. Emily Andaya, an internist who helms a cardiometabolic practice in Indiana, US, that focuses on the liver. 00:14:23 - Roundtable Part I: Groundbreaker and introductionThe core of the episodes started during the weekly groundbreakers, as guests began to describe the path that brought them from single-disease specialization to the broader multi-metabolic practice.. Immediately after the groundbreakers, participants describe their clinics today, including patient population and principles underlying their approach to treatment.00:26:15 - Roundtable Part II: Tools they useGuided by Louise, the specialists discuss the devices they use to screen and stage patients and the drugs they use to treat them. One interesting item that emerges is that EDOM relies on a 0-to-4 disease severity classification, but it does not align point-by-point with the 4-point fibrosis scale common in MASH. 00:40:28 - Roundtable Part III: Training Providers in the ClinicsLouise starts this segment by asking the EDOM team how they train practitioners in their clinic. EDOM trains practitioners in nutrition and technologists in the proper use of scanning devices. Karen comments that one big issue in re-training involves the length of visits: 15 minutes for a typical GI visit vs. 60 minutes for an initial multi-metabolic session and 30 minutes for follow-ups. Along with this, the information gathering technique are different.00:50:57 - Roundtable Part IV: Patient Health and Wrap-upLouise asks participants whether and how they have measured the impact the multi-metabolic approach has on patients' health (profound in both cases) and whether they are seeing an increase in HCC. Karen sees a difference among her long-term patients, while EDOM refers patients before their fibrosis reaches cirrhosis stage. In the last part of the episode, panelists share perspectives on how their initial specialties fit with the broader multi-metabolic practice and the kinds of impact they can have on patients.01:12:50 - Expert: Dr. Emily Andaya discusses US initiatives in multi-metabolic healthThis week's expert is Dr. Emily Andaya, an Indiana (US)-based internist whose practice has expanded to take on a multi-metabolic focus. She begins by discussing her recent attendance at the American Society for Preventive Cardiology (SPC) meeting in Boston, where she heard a talk by Dr. Christos Montzoros, an endocrinologist and multi-metabolic advocate, who emphasized the importance of incorporating the liver into preventive cardiology's focus. Louise and Emily agree that cardiometabolic focus involves evaluating general, overall health, but Emily discusses how this might require a deeper or broader testing protocol for each target organ. Emily describes the 4-point CKM scale and Louise asks how fibrosis or NAS scoring, as deployed in the MASH CRN system, might be valuable here. This is a far-ranging conversation, but one special point of interest involves the psychological benefit of telling a patient they need to treat one (multi-metabolic) condition, instead of separate heart, kidney, endocrinological and liver conditions, which might feel far more overwhelming. 01:48:48 - ConclusionBecause Roger is on vacation, there is no business report this week.

Feeling drained by IBD—physically and emotionally? Discover how to reclaim your strength beyond the flare with proven strategies from leading clinical psychologist and resilience expert Dr. Laurie Keefer. Living with Crohn's disease or ulcerative colitis isn't just about managing physical symptoms—it's about coping with the emotional, social, and mental toll that IBD can take. From how you see yourself, to how you eat, connect with others, and face the unknown, the impact can be profound. In this powerful episode, Dr. Keefer—author of the groundbreaking American Journal of Gastroenterology article “Beyond Depression and Anxiety in IBD: Forging a Path Toward Emotional Healing”—shares what it truly means to heal beyond the flare. You'll learn: What emotional resilience really looks like for people living with IBD How trauma, disordered eating, and adjustment disorders can surface with chronic illness How to start building emotional strength today using Dr. Keefer's Resilience5™ framework This episode is produced in collaboration with the American College of Gastroenterology's Patient Care Committee.  

Send us a textWhat happens when your body declares war on multiple organs? Julie Davis knows this reality all too well. Her medical journey began with a celiac disease diagnosis at 18, followed by ulcerative colitis in college, but it was the sudden onset of autoimmune pancreatitis in 2011 that turned her world upside down.Julie's story is remarkable not just for the rare combination of conditions she manages, but for the extraordinary resilience she's shown throughout her journey. As a dietitian who became a physician's assistant while battling debilitating pancreatitis flares, Julie brings unique perspective from both sides of healthcare. She takes us through the harrowing experience of multiple hospitalizations, specialists puzzling over her case at Mayo Clinic, and ultimately, the life-altering decision to have her pancreas completely removed in 2023.The procedure—called total pancreatectomy with islet cell autotransplantation—is so rare that Julie couldn't find a single podcast about it. Her pancreatic cells were extracted and transplanted into her liver, turning her into what she describes as "essentially a type 1 diabetic" overnight. Despite this dramatic medical intervention and the insulin pump she now relies on, Julie's perspective remains incredibly positive.Perhaps most inspiring is how Julie has refused to let her health conditions define her limitations. She completed PA school despite having an endoscopy and nerve block the same morning as important exams. She had three children through IVF while managing multiple autoimmune conditions. And today, she's passing on her hard-won wisdom to her daughter, who has inherited celiac disease.Julie's message to fellow chronic illness warriors rings clear: "It doesn't define you. You can still do things that you love." Her extraordinary journey demonstrates that even the most complex medical challenges can't stand in the way of a determined spirit pursuing a fulfilling career, family life, and future.Links: The Juicebox PodcastMission Cure: Nonprofit working in improve quality of life and bring more treatments to chronic pancreatitis Let's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

In our last episode of the Bowel Sounds Summer School series (at least for this year), hosts Dr. Jason Silverman and Dr. Jennifer Lee have gathered highlights from past episodes on endoscopy to create an episode filled with clinical and teaching pearls.  Former expert guests Dr. Jenifer Lightdale, Dr. Catharine Walsh, and Dr. Looi Ee explain the elements of quality endoscopy, how to teach endoscopy, perform difficult colonoscopies, and even how to keep endoscopists healthy throughout their career.Be sure to also check out the great hands-on, colonoscopy skills and train the trainer workshops held during the NASPGHAN Annual Meeting each year!Our Bowel Sounds Summer School series includes four episodes on big topics in our field, artisanally crafted for the ears of learners of all stages from the young student to the seasoned attending.Learning Objectives:Review the technical and non-technical components of quality endoscopic procedures.Understand communication strategies that help preceptors effectively teach endoscopy skills to trainees.Review the relevant elements of ergonomics and systemic factors that can help prevent endoscopy-related injuries. Featured Episodes:Jenifer Lightdale - PEnQuINs and Making Pediatric Endoscopy Safer (November 2020)Catharine Walsh - Education in Endoscopy (November 2022)Looi Ee - The Challenging Colonoscopy: Down Under Edition (August 2023)Links:NASPGHAN/ESPGHAN Society Papers on Endoscopy (2022)Other Summer School Episodes:Bowel Sounds Summer School - Constipation in ChildrenBowel Sounds Summer School - Eosinophilic EsophagitisBowel SoundsSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Dr. Mira Slizovsky will discuss the most common reasons parents consider giving supplements to their children and advice on when they might be needed.

Tiago Arnaud convida Djoni Moraes, Internista pelo HCFMUSP, para discutir um caso clínico de vômitos recorrentes e diarreia apresentado pela Ana Carolina Malvaccini.Referencias:1. https://www.tadeclinicagem.com.br/guia/381/abordagem-a-diarreia-cronica/2. Tome J, Kamboj AK, Sweetser S. A Practical 5-Step Approach to Nausea and Vomiting. Mayo Clin Proc. 2022;97(3):600-608. doi:10.1016/j.mayocp.2021.10.0303. Arasaradnam RP, Brown S, Forbes A, et al. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut. 2018;67(8):1380-1399. doi:10.1136/gutjnl-2017-3159094. Schiller LR, Pardi DS, Sellin JH. Chronic Diarrhea: Diagnosis and Management. Clin Gastroenterol Hepatol. 2017;15(2):182-193.e3. doi:10.1016/j.cgh.2016.07.0285. BONIS, Peter AL; LAMONT, J. Thomas. Approach to the adult with chronic diarrhea in resource-abundant settings. 2022.

We're welcoming back Dr. Ali Navidi, a licensed clinical psychologist, and co-founder of GI Psychology.  Today, Dr. Navidi is here to tell us all about the IBD Therapy Group—offered in partnership with the American College of Gastroenterology and the Crohn's & Colitis Foundation. This 8-week, nationwide, virtual therapy program is designed for patients with Crohn's Disease and Ulcerative Colitis and uses two proven approaches—Cognitive Behavioral Therapy (CBT) and Gut-Directed Hypnotherapy—to help manage stress, anxiety, and inflammation, which can all contribute to IBD flare-ups.  Hear Dr. Navidi discuss… The brain-gut connection and how it can impact IBD The benefits and patient outcomes of CBT and Gut-Directed Hypnotherapy What patients can expect from the IBD Therapy Group  The IBD Therapy Groups starts on August 14. To learn more, see if you qualify, or sign up for a free consultation, visit https://www.gipsychology.com/ibdgroup/.  

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Tao Zuo from the Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, Guangdong, China, on the paper "Dietary whey protein protects against Crohn's disease by orchestrating cross-kingdom interaction between the gut phageome and bacteriome" published in paper copy in Gut in August 2025.   Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://spoti.fi/3Ifxq9p).

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. I hope you are all enjoying the summer and that your IT treats you well. In this podcast, we have two new studies to think about.First, should children with gastroenteritis be given anti-emetics? Would ondansetron help and improve outcomes? Second, can methotrexate help knee osteoarthritis? It would be great if this would work, but hope only gets us so far. What does the research show? ReferencesNEJM Ondansetron in GE in kidsJAMA Int Med Methotrexate and knee OAwww.nbmedical.com/podcast

In today's episode of The Root Cause Medicine Podcast, Dr. Kate Kresge dives into men's health, neurology, and fertility with Dr. Eric Yarnell. You'll hear us discuss: 1. Testosterone and its impact on the male body 2. The dangers of relying on Internet medical information 3. Addressing male factors in infertility treatment 4. The role of herbal medicine in optimizing testosterone production 5. High testosterone and prostate conditions 6. How diet and gut health influence prostate health Dr. Eric Yarnell is the President of Northwest Naturopathic Urology, focusing on men's health, urology, and nephrology. He is also a Professor at Bastyr University in the Department of Botanical Medicine, alongside running two businesses in botanical medicine and publishing. He is the author of numerous texts and articles, including Natural Approach to Gastroenterology, Natural Approach to Urology, Natural Approach to Prostate Conditions, and Naturopathic Nephrology. Order tests through Rupa Health, the BEST place to order functional medicine lab tests from 30+ labs - https://www.rupahealth.com/reference-guide

Send us a text** Warning that this episode talks very candidly and descriptively about surgery and more.** Few IBD stories contain as many twists, complications, and near-death experiences as Bryan Schulze's journey with ulcerative colitis. What began with occasional bleeding during his military deployment escalated into a life-threatening medical emergency when doctors discovered he had been hemorrhaging internally for months. With severe anemia and barely conscious, Bryan's introduction to IBD came with a stark realization — he had been slowly dying without knowing it.Bryan's candid account takes us through the harrowing reality of military service with undiagnosed IBD, the struggle to maintain dignity while bleeding profusely, and the complex surgeries that followed. After medication failures and complications that defy belief, Bryan underwent a full colectomy and J-pouch surgery that led to severe complications including a massive abdominal infection, wound vacuum treatments, and catastrophic surgical errors. Beyond the physical trauma, Bryan shares the emotional and professional toll of IBD. From workplace discrimination to failed career dreams, steroid-induced diabetes to heart failure, and battles with depression and anxiety — his story encompasses the full spectrum of challenges IBD patients may face. Yet through it all, Bryan found his way back through support from his family, reconnection with his faith, and an indomitable will to live.Now serving as a police officer with a permanent ostomy bag, Bryan offers powerful wisdom to fellow IBD warriors: "Take a deep breath. It's not a life ender. It is a life changer. Be willing to adapt with it so that you can overcome it and still live the life that you were given to live." His message of resilience serves as a beacon for anyone facing seemingly insurmountable health challenges.Have you been struggling with IBD? Share your story or questions with us, and remember that no matter how difficult your journey, you're never alone in this fight.Links: Our episode with Dr. Anish PatelOur episode with Matty Bowels! Veterans with IBD Support Group- Cron's & Colitis Foundation USAAbout IBD Podcast episode with Dr. Anish PatelJohn's story of serving in the Royal Marines in the UK- Crohn's & Colitis UIKLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Fecal incontinence is more common than people realize, but patients are often embarrassed to discuss with their doctor. Dr. Reidy discusses causes, diagnosis and treatment options.

In the eighth episode of season 4, special host Dr. Cara English, Chief Executive Officer (CEO) and Chief Academic Officer (CAO) of Cummings Graduate Institute for Behavioral Health Studies (CGI), sits down with Dr. David Clarke, President and Co-Founder of the Association for the Treatment of Neuroplastic Symptoms. Together, they look into the emerging science of neuroplastic pain, which are chronic symptoms caused by learned neural pathways in the brain rather than disease or injury. Dr. Clarke shares how these misunderstood conditions are being redefined through the lens of mind-body medicine. Tune in to explore how neuroplasticity is reshaping our understanding of chronic illness.About the Special Host:Dr. Cara English, DBH is the Chief Executive Officer and Chief Academic Officer of Cummings Graduate Institute for Behavioral Health Studies (CGI) and Founder of Terra's Tribe, a maternal mental health advocacy organization in Phoenix, Arizona. Dr. English spearheaded a perinatal behavioral health integration project at Willow Birth Center from 2016 to 2020 that received international acclaim through the publication of outcomes in the International Journal of Integrated Care. Dr. English served as Vice-President of the Postpartum Support International – Arizona Chapter Founding Board of Directors and co-chaired the Education and Legislative Advocacy Committees. She currently serves on the Maternal Mortality Review Program and the Maternal Health Taskforce for the State of Arizona. She served as one of three Arizonan 2020 Mom Nonprofit Policy Fellows in 2021. For her work to establish Cummings Graduate Institute for Behavioral Health Studies, Cara was awarded the Psyche Award from the Nicholas & Dorothy Cummings Foundation in 2018 and is more recently the recipient of the 2022 Sierra Tucson Compassion Recognition for her work to improve perinatal mental health integration in Arizona.About the Guest:David D. Clarke, MD is President of the Association for Treatment of Neuroplastic Symptoms, and Clinical Assistant Professor of Gastroenterology Emeritus at Oregon Health & Science University in Portland, Oregon.  He is board-certified in Gastroenterology and Internal Medicine and has treated over 7000 patients whose symptoms were not explained by disease or injury but rather by stress or trauma. His book for patients, They Can't Find Anything Wrong!, was praised by a president of the American Psychosomatic Society as “truly remarkable.” He has also edited two textbooks on stress-based conditions, co-produced three documentary films, lectures across North America and Europe and has done hundreds of interviews for TV, Radio, and podcasts.www.Symptomatic.me 

What if your persistent unexplained chronic pain or illness isn't just physical? Neuroplastic symptoms describe chronic pain or illness that defies conventional medical explanations, and Dr. David D. Clarke, a pioneering expert in neuroplastic symptoms and mind-body healing, has dedicated his career to uncovering the profound links between stress, grief, trauma, and physical symptoms. As President of the Association for Treatment of Neuroplastic Symptoms, and Clinical Assistant Professor of Gastroenterology and Americans at Oregon Health and Science University, Dr. Clarke shares invaluable insights on common neuroplastic conditions, personal traits linked to these symptoms, and how they can be effectively diagnosed and treated, offering hope and highlighting the possibility of healing for those struggling with chronic pain or illness who have been told "they can't find anything wrong."WATCH ON YOUTUBE: Can Unexplained Chronic Pain Be Linked to Grief, Trauma, and Stress?IN THIS EPISODE, YOU'LL HEAR ABOUT THINGS LIKE:How unresolved emotional distress can manifest as chronic pain or illness.Common neuroplastic conditions and personal traits linked to these symptoms.The five common types of stress that are emotionally painful experiences.How neuroplastic symptoms can be effectively diagnosed and treated.The concept of stress illness and its evolution into a widespread epidemic.The difference between visible and invisible illnesses and the importance of listening without judgment.The "neuroplastic self-quiz" and its purpose.The importance of finding joy in life and aligning skills with what the world needs.Grab Dr. Clarke's They Can't Find Anything Wrong!: 7 Keys to Understanding, Treating, and Healing Stress IllnessBecome a member of ATNS: https://www.symptomatic.me/membership---✨ Grief & Rebirth: Healing Resources & Tools ✨

Host: Darryl S. Chutka, M.D. Guest: Sunanda V. Kane, M.D. Most people who develop inflammatory bowel disease are diagnosed before the age of 30. In women, this often occurs during the middle of their reproductive years. Some with inflammatory bowel disease choose to avoid pregnancy, usually due to misconceptions about pregnancy risks. Yet if properly managed, women can experience a normal, uneventful pregnancy and deliver a healthy child.  What effect does inflammatory bowel disease have on fertility? Do patients have a greater chance of a normal pregnancy if the bowel disease is in remission? How can patients minimize the risk of inflammatory bowel disease flares during pregnancy and are the pharmacologic therapies commonly used to treat inflammatory bowel disease safe to use during pregnancy? These are some of the questions I'll ask my guest, Sunanda V. Kane, M.D., from the Division of Gastroenterology and Hepatology at the Mayo Clinic as we discuss “Inflammatory Bowel Disease and Pregnancy”. https://ce.mayo.edu/content/mayo-clinic-talks-inflammatory-bowel-disease Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts 

GLP-1 medications like Ozempic (semaglutide), Wegovy, and Mounjaro (tirzepatide) have transformed treatment for type 2 diabetes and weight loss — but they can also cause digestive side effects like nausea, diarrhea, constipation, bloating, and stomach pain that leave many patients confused or worried. In this episode, we're joined by Dr. Catherine Hudson from LSU Health New Orleans to separate fact from fiction and provide clear, evidence-based guidance. Dr. Hudson breaks down: How GLP-1 receptor agonists work Common digestive side effects—and how to manage them Why lifestyle changes still matter What you need to know before surgery or GI procedures when taking these medications Whether you're a patient, caregiver, or healthcare provider, this episode offers practical insights to help you navigate the GLP-1 journey with confidence. This episode is presented in collaboration with the American College of Gastroenterology's Patient Care Committee.  

Send us a textKimberly LaRose's journey from a nine-year diagnostic odyssey to creating an award-winning vodka demonstrates the remarkable resilience found in the IBD community. After struggling with unexplained symptoms that doctors repeatedly misdiagnosed, Kimberly finally received her Crohn's disease diagnosis and discovered that gluten and corn were major inflammation triggers for her body.Rather than seeing her dietary restrictions as limitations, Kimberly embraced a philosophy of "replacing, not removing." This positive mindset would prove transformative when she attended an event where she couldn't eat or drink anything due to her restrictions. What began as a half-joking call to a friend about creating their own vodka evolved into Wisher Vodka – a sugar beet-based spirit that's gluten-free, grain-free, and vegan.The path from concept to award-winning product wasn't simple. Kimberly and her co-founder Emily researched 300 distillers, visited 60 personally, and developed a unique production process that includes lab testing every batch to ensure purity. Their commitment to quality and transparency has earned them multiple prestigious awards, including Grand Vodka of the Year with a remarkable 98-point taste rating from the Bartender Spirits Award.Beyond the business success, Kimberly's story highlights how health challenges can unexpectedly open new doors. "I wouldn't have created Wisher had I not been diagnosed with Crohn's," she reflects. Her work supporting the Crohn's and Colitis Foundation further demonstrates her commitment to the IBD community that sparked her entrepreneurial journey.Whether you're navigating dietary restrictions, seeking inspiration for managing chronic illness, or simply appreciate the story behind your spirits, Kimberly's journey reminds us that sometimes our greatest struggles lead to our most meaningful creations. Links: Sip with Confidence! - Wisher Vodka's websiteCocktail recipesLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Dr. Carole Keim talks with Dr. Victoria Martin, MD, MPH, a gastroenterologist, a specialist who focuses on everything related to the stomach and intestines in babies. Dr. Martin trained in pediatrics and became interested in what happens in baby intestines, especially early on, during training. She talks with Dr. Keim about things like blood in a baby's stool, protein allergies, signs of food allergies in children, and what to look for at home for signs of intestinal distress. She differentiates between what might be cause for concern versus what is normal for infants regarding reflux, breastfeeding, constipation, and more.Dr. Martin explains normal reflux in babies and what to try at home before getting to a doctor's appointment in regards to concerns about too much spitting up. She and Dr. Keim discuss food allergies in infants, common concerns over what allergens are transferred from a mother's breastmilk, and why there are things to consider before immediately eliminating foods from a mother's diet if an allergy is suspected. Food allergies, causes, and substitute formulas are discussed, and Dr. Martin shares insights into possibilities for preventing the development of allergies, when to introduce solid foods, and what a baby's poop reveals about the baby's health. It's an episode full of practical advice and in-depth knowledge from Dr. Martin about babies' intestinal functions.    About Dr. Victoria Martin, MD, MPH:Dr. Martin graduated from Harvard University with a degree in Biology. She completed her medical school and residency training in Pediatrics at the University of Massachusetts Medical School. She then completed her fellowship training at the Massachusetts General Hospital for Children in the division of Pediatric Gastroenterology and Nutrition, during which she was awarded the Outstanding Teaching Award by the pediatric housestaff. She also completed a Master's degree in Public Health in Clinical Effectiveness at the Harvard School of Public Health.Dr. Martin's clinical and research interests include the developing infant microbiome and its potential role in gastrointestinal food allergic diseases, including allergic proctocolitis and eosinophilic esophagitis.__ Resources discussed in this episode:The Holistic Mamas Handbook is available on AmazonThe Baby Manual is also available on Amazon__Contact Dr. Carole Keim MDLinktree: linktr.ee/drkeimTiktok: @dr.keimInstagram: @doctoratyourdoor Contact Dr. Victoria Martin, MD, MPHWorkplace: Mass General Brigham for ChildrenLinkedIn: Victoria-Mackenzie-Martin-644337102

In the corner of the ICU, on multiple pressors, distended, oliguric, and intubated you'll find the necrotizing pancreatitis patient. Sounds intimidating, but with the persistence, patience, and the proper care these patients can make it! In this episode from the HPB team at Behind the Knife listen in as we discuss the Step-Up approach, when to surgically intervene, various approaches to pancreatic Necrosectomy, and additional aspects of the multidisciplinary care required for the successful treatment of necrotizing pancreatitis.  Hosts Anish J. Jain MD (@anishjayjain) is a current PGY3 General Surgery Resident at Stanford University and a former T32 Research Fellow at the University of Texas MD Anderson Cancer Center. Jon M. Harrison is a 2nd year HPB Surgery Fellow at Stanford University. He will be joining as faculty at the Massachusetts General Hospital in Boston, MA at the conclusion of his fellowship in July 2024.    Learning Objectives ·      Develop an understanding of the severity of necrotizing pancreatitis and the proper indications to surgical intervene on this often-tenuous patients.  ·      Develop an understanding of the Step-Up approach and key aspects (reimaging, clinical status, physiologic status, etc.) that determine when to “step-up” treatment for patients with necrotizing pancreatitis. ·      Develop an understanding of long term sequalae and complications associated with necrotizing pancreatitis and operative management ·      Develop an understanding of multidisciplinary care and long-term follow-up necessary for adequate treatment of patients suffering from necrotizing pancreatitis. Suggested Reading Maurer LR, Fagenholz PJ. Contemporary Surgical Management of Pancreatic Necrosis. JAMA Surg. 2023;158(1):81–88. doi:10.1001/jamasurg.2022.5695 https://pubmed.ncbi.nlm.nih.gov/36383374/ Harrison JM, Day H, Arnow K, Ngongoni RF, Joseph A, Aldridge T, Wheeler KJ, DeLong JC, Bergquist JR, Worth PJ, Dua MM, Friedland S, Park W, Eldika S, Hwang JH, Visser BC. What's Behind it all: A Retrospective Cohort Study of Retrogastric Pancreatic Necrosis Management. Ann Surg. 2024 Sep 3. doi: 10.1097/SLA.0000000000006521. https://pubmed.ncbi.nlm.nih.gov/39225420/ Harrison JM, Visser BC. Not Dead Yet: Managing the Abdominal Catastrophe in Necrotizing Pancreatitis. Pancreas. 2025 May 20. doi: 10.1097/MPA.0000000000002512. https://pubmed.ncbi.nlm.nih.gov/40388698/ Harrison JM, Li AY, Sceats LA, Bergquist JR, Dua MM, Visser BC. Two-Port Minimally Invasive Nephrolaparoscopic Retroperitoneal Debridement for Pancreatic Necrosis. J Am Coll Surg. 2024 Dec 1;239(6):e7-e12. doi: 10.1097/XCS.0000000000001152. https://pubmed.ncbi.nlm.nih.gov/39051721/ van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, van Goor H, Schaapherder AF, van Eijck CH, Bollen TL, van Ramshorst B, Nieuwenhuijs VB, Timmer R, Laméris JS, Kruyt PM, Manusama ER, van der Harst E, van der Schelling GP, Karsten T, Hesselink EJ, van Laarhoven CJ, Rosman C, Bosscha K, de Wit RJ, Houdijk AP, van Leeuwen MS, Buskens E, Gooszen HG; Dutch Pancreatitis Study Group. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med. 2010 Apr 22;362(16):1491-502. doi: 10.1056/NEJMoa0908821. https://pubmed.ncbi.nlm.nih.gov/20410514/ Bang JY, Arnoletti JP, Holt BA, Sutton B, Hasan MK, Navaneethan U, Feranec N, Wilcox CM, Tharian B, Hawes RH, Varadarajulu S. An Endoscopic Transluminal Approach, Compared With Minimally Invasive Surgery, Reduces Complications and Costs for Patients With Necrotizing Pancreatitis. Gastroenterology. 2019 Mar;156(4):1027-1040.e3. doi: 10.1053/j.gastro.2018.11.031. https://pubmed.ncbi.nlm.nih.gov/30452918/ Zyromski NJ, Nakeeb A, House MG, Jester AL. Transgastric Pancreatic Necrosectomy: How I Do It. J Gastrointest Surg. 2016 Feb;20(2):445-9. doi: 10.1007/s11605-015-3058-y. https://pubmed.ncbi.nlm.nih.gov/26691148/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

In this episode, Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH​, discusses the most recent developments in primary biliary cholangitis (PBC) treatment, including cutting-edge data on new and emerging agents and how these updates may be integrated into your practice. Topics include:Steatotic liver disease and PBCVibration-controlled transient elastography (VCTE) and discordant biochemical responses in PBCPPAR agonists and IBATs for PBC treatment Presenter:Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGHAssociate ProfessorNIHR Birmingham BRCUniversity of BirminghamConsultant Hepatologist, Liver UnitUniversity Hospitals BirminghamBirmingham, United Kingdom Link to full program: https://bit.ly/44ySoL3Follow along with the slides: https://bit.ly/3IvwQrjGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH​, discusses the most recent developments in primary biliary cholangitis (PBC) treatment, including cutting-edge data on new and emerging agents and how these updates may be integrated into your practice. Topics include:Steatotic liver disease and PBCVibration-controlled transient elastography (VCTE) and discordant biochemical responses in PBCPPAR agonists and IBATs for PBC treatment Presenter:Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGHAssociate ProfessorNIHR Birmingham BRCUniversity of BirminghamConsultant Hepatologist, Liver UnitUniversity Hospitals BirminghamBirmingham, United Kingdom Link to full program: https://bit.ly/4lKaO2HFollow along with the slides: https://bit.ly/44PPBysGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

Host: Darryl S. Chutka, M.D. Guest: Edward V. Loftus JR, M.D. Inflammatory Bowel Disease is somewhat of an umbrella term for a group of chronic inflammatory conditions of the GI tract. The most common types include ulcerative colitis and Crohn's Disease. While there are similarities between the two, there are also differences. For many individuals with inflammatory bowel disease, it's only a mild illness. Unfortunately for some, it can lead to severe disability and potentially life-threatening complications. What are the similarities and differences between ulcerative colitis and Crohn's? When should we suspect a patient has an inflammatory bowel disease? What's the best way to establish a diagnosis and finally, what treatment options do we have? These are just some of the questions I'll be asking my guest, Edward V. Loftus JR, M.D., from the Division of Gastroenterology and Hepatology at the Mayo Clinic as we discuss “Inflammatory Bowel Disease and Its Treatment”. https://ce.mayo.edu/content/mayo-clinic-talks-inflammatory-bowel-disease Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts 

Send us a textNavigating the workplace while managing inflammatory bowel disease can feel like walking a tightrope—balancing health needs against career responsibilities. This episode cuts through the confusion with straightforward, practical advice from someone who truly understands both sides of the equation.Employment attorney Abbe Feitelberg returns to share her unique perspective as both an IBD patient and legal expert. She breaks down the Family Medical Leave Act (FMLA) and Americans with Disabilities Act (ADA) in clear, accessible terms that empower you to advocate for yourself in any workplace situation. From understanding which companies must comply with these laws to learning exactly what paperwork you need, Abbe demystifies the process of securing your workplace rights.The conversation explores common misconceptions, like believing managers need detailed medical information (they don't!) or that requesting accommodations might hurt your career (it shouldn't!). You'll discover practical strategies for maintaining privacy while getting the support you need, whether that's intermittent leave for treatments, flexible scheduling during flares, or immediate bathroom access. Most importantly, you'll learn how to document everything properly to protect yourself if issues arise.What makes this episode particularly valuable is how it addresses real-world scenarios: When should you disclose your condition? What happens if your accommodation request is denied? How do you balance transparency with privacy? As Abbe points out, "These protections exist to help you succeed—never be afraid to ask for what you need." Whether you're currently employed, job hunting, or supporting someone with IBD, this episode provides crucial knowledge to navigate workplace challenges with confidence and dignity.Links: Abbe's first episode with usUS Equal Employment Opportunity CommissionInfo on the Americans with Disabilities ActInfo on the Family Medical Leave ActEmployee and Employer resources- Crohn's & Colitis Foundation- USALet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Host: Darryl S. Chutka, M.D. Guests: David H. Bruining, M.D., and Nayantara Coelho-Prabhu, M.B.B.S. An early diagnosis of inflammatory bowel disease is important in preventing long-term complications. Prompt treatment can improve quality of life, reduce the likelihood of hospitalizations, and help maintain remissions. However, establishing a diagnosis is often challenging due to the nonspecific and fluctuating nature of symptoms. Inflammatory bowel disease can also mimic other GI conditions. In addition, diagnostic confirmation usually requires a combination of blood tests, imaging, endoscopy, and histological analysis, making the process both time consuming and complex.  The topic for today's podcast is “Diagnosing Inflammatory Bowel Disease and Monitoring Modalities” and my guests are David H. Bruining, M.D., and Nayantara Coelho-Prabhu, M.B.B.S., from the Division of Gastroenterology and Hepatology at the Rochester campus of the Mayo Clinic. https://ce.mayo.edu/content/mayo-clinic-talks-inflammatory-bowel-disease   Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts   

Welcome to the Choosing Wisely Campaign series! This is the third episode of a 6-part series exploring the ABIM Foundation's Choosing Wisely Lists. This campaign aims to promote conversations between clinicians and patients to avoid unnecessary medical tests, treatments, and procedures. Our second case-based episode presents an infant with diarrhea and diaper dermatitis. After a clear discussion of the case and thoughtful consideration of the etiology and treatment strategies, we use the AAP's Choosing Wisely dermatology and gastroenterology, hepatology, and nutrition lists to create a resource-conscious care plan that is safe and patient-centered. In the coming episodes, we'll explore the pediatric lists and apply our knowledge to cases of common presentations seen in primary and acute care pediatrics.    Series Learning Objectives: Introduction to the Choosing Wisely Campaign: Understand the origins, historical precedent, and primary goals of the campaign. Case-Based Applications: Explore five common presentations in primary and acute care pediatrics, applying concepts from various Choosing Wisely lists to guide management and resource stewardship. Effective Communication: Learn strategies for engaging in tough conversations with parents and colleagues to create allies and ensure evidence-based practices are followed. Modified rMETRIQ Score: 15/15   Competencies: AACN Essentials: 1: 1.1 g, 1.2f, 1.3de 2: 2.1 de, 2.2g, 2.4fg, 2.5 hijk 7: 7.2 ghk 9: 9.1ij, 9.2ij, 9.3ik NONPF NP Core Competencies: 1: NP1.1h, NP 1.2km, NP 1.3fjh 2: NP2.1jg, NP2.2kn, NP 2.4hi, NP2.5 klmno 7: NP7.2m 9: NP9.1mn, NP9.2n, NP9.3p   References ABIM Foundation. (2019). Communicating about overuse with vulnerable populations. Retrieved from https://www.choosingwisely.org/files/Communicating-About-Overuse-to-Vulnerable-Population_Final2.pdf AAP Section on Dermatology. (2021). Five things physicians and patients should question. https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWDermatology.pdf AAP Section on Gastroenterology, Hepatology, and Nutrition. (2023). Five things physicians and patients should question. https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWGastroenterology.pdf Harriet Lane Service (Johns Hopkins Hospital), Anderson, C. C., Kapoor, S., & Mark, T. E. (2024). The Harriet Lane handbook: a manual for pediatric house officers (23rd ed.). Elsevier.  Jauregui, J., Nelson, D., Choo, E., Stearns, B., Levine, A. C., Liebmann, O., & Shah, S. P. (2014). External validation and comparison of three pediatric clinical dehydration scales. PloS one, 9(5), e95739. https://doi.org/10.1371/journal.pone.0095739 Johnson, H., & Yu, J. (2022). Current and Emerging Therapies in Pediatric Atopic Dermatitis. Dermatology and therapy, 12(12), 2691–2703. https://doi.org/10.1007/s13555-022-00829-4 Semon, A. K., Keenan, O., & Zackular, J. P. (2021). Clostridioides difficile and the Microbiota Early in Life. Journal of the Pediatric Infectious Diseases Society, 10(Supplement_3), S3–S7. https://doi.org/10.1093/jpids/piab063

Dariush Mozaffarian is the director of the Food is Medicine Institute at the Friedman School of Nutrition Science and Policy at Tufts University and a professor of medicine at Tufts University School of Medicine. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D. Mozaffarian. Regulatory Policy to Address Ultraprocessed Foods. N Engl J Med 2025;392:2393-2396.

Still struggling with IBS symptoms, even after trying everything?   It might not be “just IBS.”   In the first episode of The Gut Show, Season 8, Dr. Mark Pimentel breaks down the connection between SIBO, IMO, ISO, and IBS, and what patients need to know about testing, treatment, and what's actually causing your symptoms.   We talked about breath tests, stool tests, probiotics, antibiotics (like Rifaximin + Neomycin), the meds that cause SIBO, and more.   Covered in this episode: Introducing Dr. Pimentel, MD [2:18] What is SIBO, ISO and IMO? [3:18] Should everyone with IBS do breath testing? [7:14] New guidelines that have come out [9:50] How should a patient navigate testing? [11:11] What about stool testing? [13:16] Negative test + symptoms or positive test without symptoms [16:50] What does normal mean? [18:44] Who does all 3 [20:39] Glucose vs Lactulose for the test [21:05] What causes these overgrowths? [21:52] The medication that WILL make you have SIBO [23:53] MAST cells, IBD, endometriosis [24:34] Treatment [32:07] Rifaximin [34:19] Any Statin or seaweed based treatment updates? [37:51] Neomycin [39:25] Elemental diet [41:23] What Dr. Pimentel wants for his patients [45:17] Probiotics [46:40] The role of metabolic disorders [48:22] Rapid fire questions [50:59]   Mentioned in this episode:  MASTER Method Membership Take the quiz: What's your poop personality?      Sponsors of The Gut Show:  FODZYME is the world's first enzyme supplement specialized to target FODMAPs. When sprinkled on or mixed with high-FODMAP meals, FODZYME's novel patent-pending enzyme blend breaks down fructan, GOS and lactose before they can trigger bloating, gas and other digestive issues. With FODZYME, enjoy garlic, onion, wheat, Brussels sprouts, beans, dairy and more — worry free! Discover the power of FODZYME's digestive enzyme blend and eat the foods you love and miss. Visit fodzyme.com and save 20% off your first order with code THEGUTSHOW. One use per customer. Gemelli Biotech offers trusted, science-backed at-home tests for conditions like SIBO, IMO, ISO, and post-infectious IBS.  Their Trio-Smart breath test measures all three key gases: hydrogen, methane, and hydrogen sulfide to detect different forms of microbial overgrowth. And for those with IBS symptoms, IBS-Smart is a simple blood test that can confirm post-infectious IBS with clinical accuracy. You simply order the test, complete it at home, send it back, and get clinically backed results in about a week that you can take to your provider!  Find out which tests are right for you at getgutanswers.com and use code ERINJUDGE25 to save $25 on your order!   About our speaker: Mark Pimentel, MD, FRCP(C), is a Professor of Medicine at Cedars-Sinai and Professor of Medicine and of Gastroenterology through Geffen School of Medicine. Dr. Pimentel is also the Executive Director of the Medically Associated Science and Technology (MAST) program at Cedars-Sinai, an enterprise of physicians and researchers dedicated to the study of the gut microbiome in order to develop effective diagnostic tools and therapies to improve patient care. As a physician and researcher, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational and clinical investigations of irritable bowel syndrome (IBS) and the relationship between gut flora composition and human disease. This research led to the first ever blood tests for IBS, ibs-smart™, the only licensed and patented serologic diagnostic for irritable bowel syndrome. The test measures the levels of two validated IBS biomarkers, anti-CdtB and anti-vinculin. A pioneering expert in IBS, Dr. Pimentel's work has been published in the New England Journal of Medicine, Annals of Internal Medicine, American Journal of Physiology, American Journal of Medicine, American Journal of Gastroenterology and Digestive Diseases and Sciences, among others. Dr. Pimentel has presented at national and international medical conferences and advisory boards. He is a diplomate of the American Board of Internal Medicine (Gastroenterology,) a fellow of the Royal College of Physicians and Surgeons of Canada and a member of the American Gastroenterological Association, the American College of Gastroenterology, and the American Neurogastroenterology and Motility Society. Dr. Pimentel completed 3 years of an undergraduate degree in honors microbiology and biochemistry at the University of Manitoba, Canada. This was followed by his medical degree, and his BSc (Med) from the University of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada, where he also completed a residency in internal medicine. His medical training includes a fellowship in gastroenterology at the UCLA Affiliated Training Program.   Connect with Erin Judge, RD:  IG: https://www.instagram.com/erinjudge.rd TikTok: https://www.tiktok.com/@erinjudge.rd   Work with Gutivate:  https://gutivate.com/services